Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International Journal of Antimicrobial Agents

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijantimicag.2012.06.003PMID 22831842
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and Laboratory Standards Institute.

  2013cited by this paper
• Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

  2012cited by this paper
• Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection

  2012cited by this paper
• Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium.

  2011cited by this paper
• Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.

  2011cited by this paper
• Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.

  2010cited by this paper
• Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.

  2009cited by this paper
• Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.

  2009cited by this paper
• Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.

  2009influential reference
• Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria

  2009cited by this paper
• Rat Pneumonia and Soft-Tissue Infection Models for the Study of Acinetobacter baumannii Biology

  2008cited by this paper
• In Vitro Activity of Tigecycline against Multidrug-Resistant Acinetobacter baumannii and Selection of Tigecycline-Amikacin Synergy

  2008cited by this paper
• Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies.

  2008influential reference
• In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates.

  2007cited by this paper
• Ventilator-associated pneumonia due to colistin susceptible-only microorganisms

  2007cited by this paper
• In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

  2007cited by this paper
• In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii

  2007cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

  2006cited by this paper
• Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii

  2006cited by this paper
• Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline

  2006cited by this paper
• In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

  2006influential reference
• Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.

  2005cited by this paper
• Treatment of multidrug resistant Acinetobacter

  2005cited by this paper
• Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians

  2004cited by this paper
• Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.

  2004influential reference
• Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii

  2002influential reference
• Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods.

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229)

  1998cited by this paper
• Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem

  1997cited by this paper

• Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?

  2023cites this paper
• Risk Factors of Clonally Related, Multi, and Extensively Drug-Resistant Acinetobacter baumannii in Severely Ill COVID-19 Patients

  2023cites this paper
• Clinical Effectiveness of Tetracycline-Class Agents Based Regimens in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Single-Center Retrospective Cohort Study

  2023cites this paper
• Multiple heteroresistance to tigecycline and colistin in Acinetobacter baumannii isolates and its implications for combined antibiotic treatment

  2023cites this paper
• Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.

  2021cites this paper
• Rescuing the Last-Line Polymyxins: Achievements and Challenges

  2021cites this paper
• Rational Combinations of Polymyxins with Other Antibiotics.

  2019cites this paper
• First Case Report of Intraventricular Tigecycline in a Neonate With Extensively Drug-resistant Acinetobacter baumannii Ventriculitis.

  2019cites this paper
• The Optimal Use of the Polymyxins Before Their Time Is Up

  2019cites this paper
• Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation.

  2019cites this paper
• A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria

  2019cites this paper
• Polymyxin Antibiotics: From Laboratory Bench to Bedside

  2019influential citation
• In vitro Pharmacodynamics and PK/PD in Animals.

  2019cites this paper
• Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates

  2018cites this paper
• Salvage Use of Tigecycline for Severely Ill Children

  2018cites this paper
• Combination therapy for extensively-drug resistant gram-negative bacteria

  2017cites this paper
• Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.

  2017cites this paper
• Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.

  2017cites this paper
• In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii: A Systematic Review and Meta-Analysis

  2017cites this paper
• Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs

  2017cites this paper
• Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

  2017cites this paper
• The antibacterial activities of aditoprim and its efficacy in the treatment of swine streptococcosis

  2017influential citation
• Mouse Models of Acinetobacter baumannii Infection

  2017cites this paper
• Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.

  2016cites this paper
• Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model

  2016cites this paper
• Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.

  2016influential citation
• Synergistic combinations of polymyxins.

  2016cites this paper
• Tigecycline: Alone or in combination?

  2016influential citation
• Animal Models to Evaluate Anti-infective Pharmacodynamics

  2016cites this paper
• Polymyxin Pharmacokinetics and Pharmacodynamics

  2016cites this paper
• In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii

  2015cites this paper
• Combined therapy for multi-drug-resistant Acinetobacter baumannii infection--is there evidence outside the laboratory?

  2015cites this paper
• Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.

  2015cites this paper
• Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection

  2015cites this paper
• Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

  2015cites this paper
• Clinical evaluation of tigecycline in the treatment of nosocomial infection in a hospital in Taiwan.

  2014cites this paper
• In Vitro and In Vivo Activities of Tigecycline-Colistin Combination Therapies against Carbapenem-Resistant Enterobacteriaceae

  2014cites this paper
• Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

  2014cites this paper
• Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.

  2014cites this paper
• Enterobacteriaceae against Carbapenem-Resistant Therapies Tigecycline-Colistin Combination Activities of In Vivo and In Vitro

  2014cites this paper
• A health-care associated pneumonia case due to colistin resistant Acinetobacter baumannii

  2014cites this paper
• Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date.

  2014cites this paper
• Efficacy of Sulbactam and Its Combination with Imipenem, Colistin and Tigecycline in an Experimental Model of Carbapenem-Resistant Acinetobacter baumannii Sepsis

  2014cites this paper
• International Journal of Antimicrobial Agents

  2014cites this paper
• The Acinetobacter baumannii group: a systemic review

  2013cites this paper
• In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii

  2013cites this paper
• In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii

  2013cites this paper
• The Acinetobacter baumannii group: a systemic review.

  2013cites this paper
• Clinical Characteristics in Patients with Carbapenem-Resistant Acinetobacter baumannii Isolates from Tracheal Secretions

  2013cites this paper